Zhejiang Yatai Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Xiaoming Huang

Chief executive officer

CN¥919.6k

Total compensation

CEO salary percentage	n/a
CEO tenure	2.2yrs
CEO ownership	n/a
Management average tenure	2.2yrs
Board average tenure	2.2yrs

Recent management updates

Recent updates

CEO

Xiaoming Huang (61 yo)

2.2yrs

Tenure

CN¥919,600

Compensation

Mr. Xiaoming Huang has been General Manager and Non-Independent Director of Zhejiang Yatai Pharmaceutical Co., Ltd. from April 15, 2022.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xiaoming Huang	GM & Director	no data	CN¥919.60k	no data
Jingyang Xu	Financial Director	2.2yrs	CN¥420.90k	no data
Wei Xu	Board Secretary	2.2yrs	CN¥420.80k	no data
Bao Kun Hu	Deputy General Manager	16.5yrs	CN¥442.20k	no data
Qin Shui Tan	Deputy General Manager	10.5yrs	CN¥443.00k	no data
Jianwei Cen	Deputy General Manager	2.2yrs	CN¥419.70k	no data

2.2yrs

Average Tenure

53yo

Average Age

Experienced Management: 002370's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Xiaoming Huang	GM & Director	2.2yrs	CN¥919.60k	no data
Min Tu	Supervisor	2.3yrs	no data	no data
Cai Fu	Vice Chairman of the Board	2.2yrs	no data	no data
Lingbo Song	Non-Independent Director	2.2yrs	no data	no data
Wei Huang	Non-Independent Director	2.2yrs	CN¥210.60k	no data
Yajian Zhou	Non-Independent Director	2.2yrs	CN¥228.70k	no data
Haizhou Lu	Independent Director	2.2yrs	CN¥75.10k	no data
Yuehui Liu	Independent Director	2.2yrs	CN¥75.10k	no data
Lingjie Song	Chairman	2.2yrs	no data	no data
Min Cai	Independent Director	2.2yrs	CN¥75.10k	no data
Huaying Zhou	Supervisor	2.2yrs	no data	no data
Yifeng Cai	Chairman of the Supervisory Board	2.2yrs	no data	no data

2.2yrs

Average Tenure

46.5yo

Average Age

Experienced Board: 002370's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Zhejiang Yatai Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments

Recent updates

First quarter 2024 earnings released: CN¥0.005 loss per share (vs CN¥0.005 loss in 1Q 2023)

Full year 2023 earnings released: CN¥0.02 loss per share (vs CN¥0.25 loss in FY 2022)

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

New minor risk - Share price stability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: CN¥0.028 loss per share (vs CN¥0.05 loss in 3Q 2022)

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.25 loss per share (vs CN¥0.43 loss in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.10 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 2Q 2021)

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022

First quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 1Q 2021)

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: CN¥0.10 loss per share (vs CN¥0.098 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥3.86 loss in FY 2019)

Zhejiang Yatai Pharmaceutical Co., Ltd.(XSEC:002370) dropped from S&P Global BMI Index

New 90-day high: CN¥5.45

New 90-day low: CN¥3.60

New 90-day low: CN¥4.29

New 90-day low: CN¥4.44

New 90-day low: CN¥4.77

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Earnings released

New 90-day high - CN¥6.25

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age